Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Osteosarcoma
(OS) is an aggressive malignant mesenchymal neoplasm amongst adolescents. The aim of the present study was to explore the various modes of action that
miR-379
has on the proliferation, migration, and invasion of human OS cells.
miR-379
achieves this by targetting eukaryotic initiation factor 4GII (EIF4G2). Human OS cell lines U2OS and MG-63 were selected and assigned into blank,
miR-379
mimics,
miR-379
mimic negative control (NC),
miR-379
inhibitors,
miR-379
inhibitor NC, EIF4G2 shRNA, control shRNA, and
miR-379
inhibitor + EIF4G2 shRNA group. The
miR-379
expression and
EIF4G2
mRNA expression were detected utilising quantitative real-time PCR (qRT-PCR) and the
EIF4G2 protein
expression using Western blotting. MTT assay, scratch test, Transwell assay, and flow cytometry were performed to determine the proliferation, migration, invasion, and cell cycle, respectively. In comparison with the
miR-379
mimic NC group, the
miR-379
mimics group had decreased EIF4G2 expression; the
miR-379
inhibitors group indicated an increased EIF4G2 expression. Compared with the control shRNA group, the EIF4G2 expression was lower in the EIF4G2 shRNA group and the
miR-379
expression was dropped in the
miR-379
inhibitor + EIF4G2 shRNA group. The proliferation, migration, and invasion abilities of OS cells were reduced in the
miR-379
mimics and EIF4G2 shRNA groups. The percentage of OS cells at the G
0
/G
1
stage was increased, and the percentage at the S-stage was decreased in the
miR-379
mimics and EIF4G2 shRNA groups.
miR-379
may inhibit the proliferation, migration and invasion of OS cells through the down-regulation of EIF4G2.
...
PMID:MicroRNA-379 inhibits the proliferation, migration and invasion of human osteosarcoma cells by targetting EIF4G2. 3282 Aug 9